Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biogen Inc.

www.biogen.com

Latest From Biogen Inc.

Pharma Q3 Results Preview: J&J, Roche Set The Scene

Most of the big pharma companies will report their third-quarter results over the next three weeks. As usual, Johnson & Johnson and Roche will get out of the blocks early on. Scrip considers what to expect from the two front-runners, in the first of our regular financial results previews.

Sales & Earnings Biosimilars

Yuhan Replaces Merck To Market Samsung’s Biosimilars In Korea

Local firm Yuhan is taking over from Merck as marketing partner in South Korea for Samsung Bioepis’ biosimilars amid speculation that weak sales of infliximab and etanercept may have triggered the realignment. Samsung Bioepis and Merck's broader partnership, however, remains intact.

Commercial Biosimilars

Pipeline Watch: Topline Phase III Results For Caplacizumab, Relugolix, Iclaprim

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Approvals Pipeline Watch

Merck KGaA Rules Out Major M&A, Says MS Pill Mavenclad Will Be Major Earner

The German group has been laying out its future plans to investors, which include reducing debt and a strong revenue stream from its Pfizer-partnered checkpoint inhibitor Bavencio.

M & A Cancer
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cancer
  • Cardiovascular
  • Immune Disorders
  • Inflammation
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Biogen Idec Inc.
  • Biogen Inc.
  • Idec Pharmaceutical Corp.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Company Type
  • 1st Tier Biotech
  • Parent & Subsidiaries
  • Biogen Inc.
  • Senior Management
  • Michel Vounatsos, CEO
    Alfred W Sandrock, Jr., MD, PhD, EVP, CMO
    Michael Ehlers, MD, PhD, EVP, R&D
    Jean-Paul Kress, EVP, Pres., Intl. & Head, Global Therapeutic Ops.
    Sanjay Jariwala, MD, SVP, Worldwide Medical
  • Contact Info
  • Biogen Inc.
    Phone: (617) 679-2000
    225 Binney St.
    Cambridge, MA 02142
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register